IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA Places Import Alert on Products from Two Ranbaxy Plants

10:38 AM MDT | September 18, 2008 |

Alex Scott

U.S. FDA says it has issued an import alert for officials to detain drugs reaching the U.S. border that have been made at two Indian plants owned by pharmaceutical manufacturer Ranbaxy Laboratories (Gurgaon, India). FDA says it has issued two warning letters to Ranbaxy relating to the company’s generic pharmaceutical production plants at Dewas and Paonta Sahib, India for deviating from U.S. good manufacturing practice (GMP) .  FDA says it has taken the severe action to detain product made at the plants “because of the extent and...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa